DYAX 13.08 Dyax Corp $DYAX Hit a 52 week high of 13.22

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 11:40 AM

DYAX 13.08 Dyax Corp $DYAX Hit a 52 week high of 13.22 Currently at 13.08 -0.10 -0.76% With a day low of 12.99 and a total volume of 35,867.

DYAX Dyax Corp Recent Headline News

Dyax Up 73.8% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Mon Nov 10, 4:46PM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 6 months, Dyax has returned 73.76% as of today's recent price of $13.18.
DYAX: 13.09 (-0.09)

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 13.09 (-0.09)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 13.09 (-0.09)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 13.09 (-0.09)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 13.09 (-0.09)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 328.18 (+0.31), AMAG: 34.89 (-0.02), BIND: 9.47 (-0.17), DYAX: 13.09 (-0.09)

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright
David Zanoni - at Seeking Alpha - Thu Oct 30, 11:15AM CDT

DYAX: 13.09 (-0.09)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 13.09 (-0.09)

Dyax ups earnings 87% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:53AM CDT

DYAX: 13.09 (-0.09)

Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 7:54PM CDT

DYAX: 13.09 (-0.09)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 13.09 (-0.09)

Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT

DYAX: 13.09 (-0.09)

Dyax beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:16PM CDT

DYAX: 13.09 (-0.09)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.09 (-0.09)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:35PM CDT

EA: 41.16 (-0.10), BXP: 127.93 (-0.36), AMP: 130.74 (+0.58), MRCY: 13.71 (-0.04), BLDP: 2.82 (+0.03), ESRX: 77.94 (-0.05), AJG: 48.19 (-0.07), NANO: 14.41 (-0.04), CAP: 22.66 (-0.03), EXTR: 3.76 (-0.07), HTA: 12.48 (-0.02), AEC: 19.59 (+0.10), MCK: 202.83 (+1.55), BGFV: 12.97 (+0.04), FB: 74.45 (-0.55), ARI: 16.59 (+0.01), EXP: 88.03 (+0.14), MWA: 9.96 (+0.05), DYAX: 13.09 (-0.09), FARO: 56.09 (+0.45), NFX: 33.36 (+0.10), KONA: 23.15 (+0.03), AZPN: 38.28 (+0.25), GILD: 108.65 (+1.63), HIW: 42.86 (-0.02), PEI: 21.76 (+0.03), GFIG: 5.00 (+0.14), CHRW: 71.79 (-0.38), HURN: 70.22 (-0.21), DLR: 68.40 (-0.21), HLIT: 6.78 (-0.13), AMCC: 6.29 (-0.03), INVN: 14.64 (-0.31), BOOM: 17.39 (-0.15), CINF: 51.26 (-0.17), KIM: 24.85 (-0.09), OI: 25.85 (-0.03), GPRE: 34.24 (-0.04), EPR: 57.78 (+0.30), APC: 92.56 (+0.22), IPHI: 14.73 (+0.14), HTS: 19.04 (-0.01), MAR: 77.14 (+0.58), INAP: 8.15 (-0.01), CRAY: 34.69 (+0.09), FEIC: 84.60 (+0.59), FISV: 70.12 (+0.05), DNB: 123.64 (-0.64), AFG: 60.76 (+0.07), CEB: 74.52 (-0.30), KEYW: 11.10 (+0.51), PLT: 52.36 (+0.18), MAC: 69.39 (-0.16), CHMT: 23.49 (+0.13), AFL: 59.07 (+0.01), CBT: 47.00 (+0.14), EIX: 63.10 (+0.02), EQR: 70.15 (-0.31)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 13.09 (-0.09)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.03 (-0.29), BCRX: 11.14 (-0.02), NBIX: 19.09 (+0.11), ONTY: 1.66 (-0.01), DYAX: 13.09 (-0.09)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 13.09 (-0.09)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ

YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.09 (-0.09)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 13.09 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BYD's Chip Mastery Amid China's Auto Supply Tensions

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

Midea's VitaBreeze: Revolutionizing Personalized Climate

A Fresh Breeze in Climate Control Here's something that'll shake up your household. Midea just announced their latest gizmo, called VitaBreeze, and they’re not messing around. They introduced it at IFA 2026, promising it's not just for cooling off in the summer or heating in the winter. Oh no, my friends, they've packed this unit with enough cutting-edge tech that...

ISO 45010: First Guidance for Menstruation, Menopause

Tackling Menstruation and Menopause in the Workplace Today, the International Organization for Standardization (ISO) has taken a bold step forward by launching ISO 45010—a groundbreaking standard aimed at addressing menstruation and menopause in the workplace. Millions endure these natural processes throughout their careers, yet structured policies to support them have...

Pudu D7 Robot Shines at IFA, Setting New Robotics Bar

Breaking New Ground in Robotics at IFA Well, here's a nugget for robotics buffs and investors alike: Pudu Robotics, a heavyweight in commercial service robotics, is carving out a fresh chapter with its PUDU D7. Making waves as an honoree at the IFA Innovation Awards, the D7 presents a mash-up of brains and brawn—exemplifying the future path for robotics. The PUDU D7...

Baidu's Stock Connect Inclusion: What It Means for Investors

An Intriguing Move For Baidu's Class A Shares Well, here we go again, folks. Another move on the chessboard for Baidu. They've just walked their Class A ordinary shares onto the Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connects. As of today, September 7, 2026, mainland investors can now get their mitts on these shares more easily. It might not be a...

Hyundai and UEFA: Kicking Off a Game-Changing Deal

Hyundai Drives Into Europe's Football Arena Football fever just turned electric with Hyundai allying itself with the UEFA Champions League. We're not talking about sidelines. We're smack dab in the center field of a multi-year partnership starting with the 2026/27 season. Folks, if you think this is just Hyundai shaking hands for brand exposure, think again. This is...

DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

Clover's RSV Combo Vaccine Shows Promise in Trials

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

York Space Systems Faces Class Action Over Misleading IPO

York Space Systems Under the Legal Spotlight Ever get that feeling when something just doesn’t sit right? Like a burr under the saddle, York Space Systems is now grappling with a class action lawsuit that's throwing a heap of shade on its recent moves. What’s at play? Bronstein, Gewirtz & Grossman, LLC, a law firm that seems to have a nose for corporate messes, has...

TCL’s AI Vision: Immersive Living at IFA 2026

AI and Displays: A Match Made in Tech Heaven Every so often, a company stands up at a tech fair and gives a glimpse into the next chapter of living, as TCL did at IFA 2026. This time, they're not just talking about screens; they're weaving them into the fabric of everyday life alongside AI capabilities. From sporting arenas to your living room, it's a vision of what could...